Skip to content

Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

Investigation of Coagulation Parameters in Hereditary Haemorrhagic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00230659
Enrollment
100
Registered
2005-10-03
Start date
2004-08-31
Completion date
2008-07-31
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telangiectasia, Hereditary Hemorrhagic

Brief summary

We will address coagulation parameters in hereditary haemorrhagic telangiectasia (HHT) compared to controls.

Detailed description

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable. We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state. We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.

Interventions

OTHERBlood sample to be taken.

Blood sample to be taken.

Sponsors

Hammersmith Hospitals NHS Trust
CollaboratorOTHER
Imperial College London
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients with HHT and normal controls

Exclusion criteria

* Previous thrombosis, recent ill health

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026